Psilocybin

What Is Psilocybin?

Psilocybin is a naturally occurring psychedelic compound found in over 200 species of mushrooms — most commonly Psilocybe cubensis, Psilocybe semilanceata, and Psilocybe cyanescens. When ingested, the body converts psilocybin into psilocin, which then acts on serotonin receptors in the brain to produce profound alterations in perception, emotion, and consciousness.

The mushrooms have been used for healing and spiritual purposes by indigenous cultures in Mesoamerica for at least 3,500 years. The Mazatec people of Oaxaca, Mexico — particularly the healer María Sabina — used them in veladas (healing ceremonies) to communicate with spirits and diagnose illness. The Aztecs called them teonanácatl — "flesh of the gods."

In 1957, R. Gordon Wasson became the first Westerner to participate in a Mazatec mushroom ceremony, publishing his account in Life magazine and igniting Western interest. Swiss chemist Albert Hofmann (who also synthesized LSD) isolated and identified psilocybin in 1958. By the early 1960s, Harvard psychologists Timothy Leary and Richard Alpert were conducting research — and generating controversy — that would ultimately lead to psilocybin being classified as a Schedule I substance in 1970.

Today, psilocybin is experiencing a scientific renaissance. Johns Hopkins University, NYU, Imperial College London, and dozens of other institutions are conducting rigorous clinical trials that are producing some of the most promising results in the history of psychiatry.

The Neuroscience

Psilocybin works primarily by binding to serotonin 5-HT2A receptors, which are densely concentrated in the prefrontal cortex — the brain's center for higher-order thinking, self-reflection, and emotional regulation. This binding triggers a cascade of effects that temporarily reorganize how different brain regions communicate with each other.

The most significant finding from neuroimaging studies is that psilocybin dramatically reduces activity in the Default Mode Network (DMN) — the brain network associated with self-referential thinking, rumination, and the narrative sense of "self." Depression, anxiety, addiction, and PTSD are all characterized by an overactive DMN — the mind stuck in loops of negative self-talk, worry, and past trauma. Psilocybin quiets this network, creating what researchers describe as a "reset."

Simultaneously, psilocybin dramatically increases connectivity between brain regions that do not normally communicate — a phenomenon called "hyperconnectivity." This is thought to be the neurological basis for the sense of unity, interconnectedness, and expanded perspective that people report during psilocybin experiences.

A landmark 2024 study from Washington University found that psilocybin disrupts the brain's "rich club" — a small group of highly connected hub regions that normally dominate brain communication. When these hubs are temporarily quieted, the rest of the brain is free to form new connections and patterns. This may explain why a single psilocybin session can produce lasting changes in personality, perspective, and behavior.

Psilocybin also promotes neuroplasticity — the brain's ability to form new neural connections. Studies have shown that psilocybin increases the growth of dendritic spines (the connection points between neurons) and promotes the expression of BDNF (brain-derived neurotrophic factor), a protein essential for learning and memory.

What to Expect

A psilocybin experience typically begins 20–60 minutes after ingestion and lasts 4–6 hours, with effects gradually subsiding over another 1–2 hours. The experience is highly dose-dependent.

At lower doses (1–2 grams of dried mushrooms), effects are mild: enhanced colors, gentle euphoria, heightened sensory awareness, and a sense of openness and curiosity. Many people use these doses for "microdosing" — taking sub-perceptual amounts every few days to improve mood, creativity, and focus.

At therapeutic doses (2–4 grams), the experience becomes more profound. Visual patterns may appear with eyes closed. Emotions — both difficult and beautiful — rise to the surface. Insights about relationships, patterns, and life direction often emerge with unusual clarity. The sense of ego or "self" may soften, creating a feeling of connection to something larger.

At high doses (4+ grams), the experience can be overwhelming. The ego may dissolve entirely — an experience called "ego dissolution" — producing a profound sense of unity with all existence. This can be terrifying or transcendent, depending on set and setting. This is why therapeutic psilocybin sessions are always conducted with trained guides in a carefully prepared environment.

The emotional content of a psilocybin experience is often described as "10 years of therapy in one night." Repressed memories, unresolved grief, and long-buried emotions frequently surface — not to overwhelm, but to be seen, processed, and released. The experience is not always comfortable, but it is almost always meaningful.

Conditions It Addresses

The clinical research on psilocybin is among the most exciting in modern psychiatry. Here is what the evidence shows:

Treatment-Resistant Depression: A landmark 2020 Johns Hopkins study found that two psilocybin sessions produced rapid, substantial, and sustained reductions in depression scores — with 71% of participants showing significant improvement and 54% achieving remission at four-week follow-up. A 2022 follow-up found these effects lasting up to one year. Imperial College London has replicated these findings in multiple trials.

Major Depressive Disorder: A 2021 randomized controlled trial published in the New England Journal of Medicine found psilocybin therapy comparable in efficacy to the SSRI escitalopram (Lexapro) for major depression — but with faster onset and greater improvements in emotional functioning and quality of life.

End-of-Life Anxiety: Studies at Johns Hopkins and NYU have shown that a single high-dose psilocybin session dramatically reduces death anxiety and depression in patients with life-threatening cancer diagnoses — with 80% of participants showing clinically significant improvements that persisted at 6-month follow-up.

Addiction: Psilocybin has shown remarkable results for smoking cessation (80% abstinence at 6 months in a Johns Hopkins pilot study — compared to 35% for the best pharmaceutical options), alcohol use disorder, and cocaine addiction.

OCD, PTSD, Eating Disorders: Early-phase trials are showing promising results across all three conditions.

The FDA has granted Breakthrough Therapy Designation to psilocybin for both treatment-resistant depression and major depressive disorder — the fastest regulatory pathway available.

Safety Profile

Psilocybin has one of the most favorable safety profiles of any psychoactive substance. It is physiologically non-toxic — there are no known cases of fatal overdose from psilocybin alone, and it produces no physical dependence or withdrawal syndrome.

The primary risks are psychological. In rare cases, psilocybin can trigger prolonged anxiety, psychosis, or HPPD (Hallucinogen Persisting Perception Disorder) — a condition in which visual disturbances persist after the experience. These risks are significantly elevated in people with a personal or family history of psychosis, schizophrenia, or bipolar disorder — which is why thorough screening is essential.

In a therapeutic setting with proper screening, preparation, and support, serious adverse events are extremely rare. The most common difficult experience is anxiety or emotional intensity during the session — which, when properly supported, typically resolves and often becomes the most meaningful part of the journey.

Psilocybin does not interact dangerously with most medications, but it should not be combined with lithium (risk of seizures) or taken by people on SSRIs (which can blunt or block the effects).

Legal Status

Psilocybin is a Schedule I controlled substance under US federal law, meaning it is illegal to manufacture, distribute, or possess without DEA authorization.

At the state level, the picture is changing rapidly:

Oregon (2020): First state to legalize supervised psilocybin therapy. Licensed service centers began operating in 2023.

Colorado (2022): Legalized supervised psilocybin therapy and decriminalized personal possession. Regulated access began in 2024.

Decriminalized (no arrest for personal possession): Denver, CO; Oakland, CA; Santa Cruz, CA; Seattle, WA; Ann Arbor, MI; Washington D.C.; and several others.

Internationally, psilocybin therapy is legal or decriminalized in the Netherlands (truffles), Jamaica, Brazil, and several other countries.

The FDA's Breakthrough Therapy Designation signals that federal rescheduling may follow clinical trial completion — potentially within the next 3–5 years.

At Pō a Ao, we do not currently offer psilocybin therapy. We include this information as part of our commitment to comprehensive psychedelic medicine education.

Voices of Transformation

Names changed to protect privacy. Stories shared with permission.